1. Home
  2. AUPH vs SHCO Comparison

AUPH vs SHCO Comparison

Compare AUPH & SHCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AUPH
  • SHCO
  • Stock Information
  • Founded
  • AUPH 1993
  • SHCO 1995
  • Country
  • AUPH Canada
  • SHCO United Kingdom
  • Employees
  • AUPH N/A
  • SHCO N/A
  • Industry
  • AUPH Biotechnology: Pharmaceutical Preparations
  • SHCO Hotels/Resorts
  • Sector
  • AUPH Health Care
  • SHCO Consumer Discretionary
  • Exchange
  • AUPH Nasdaq
  • SHCO Nasdaq
  • Market Cap
  • AUPH 1.1B
  • SHCO 1.0B
  • IPO Year
  • AUPH 1999
  • SHCO 2021
  • Fundamental
  • Price
  • AUPH $7.58
  • SHCO $7.87
  • Analyst Decision
  • AUPH Strong Buy
  • SHCO Buy
  • Analyst Count
  • AUPH 2
  • SHCO 2
  • Target Price
  • AUPH $11.50
  • SHCO $7.25
  • AVG Volume (30 Days)
  • AUPH 1.6M
  • SHCO 224.7K
  • Earning Date
  • AUPH 07-31-2025
  • SHCO 08-08-2025
  • Dividend Yield
  • AUPH N/A
  • SHCO N/A
  • EPS Growth
  • AUPH N/A
  • SHCO N/A
  • EPS
  • AUPH 0.27
  • SHCO N/A
  • Revenue
  • AUPH $247,295,000.00
  • SHCO $1,224,734,000.00
  • Revenue This Year
  • AUPH $12.15
  • SHCO $8.99
  • Revenue Next Year
  • AUPH $18.31
  • SHCO $6.02
  • P/E Ratio
  • AUPH $28.53
  • SHCO N/A
  • Revenue Growth
  • AUPH 29.20
  • SHCO 8.21
  • 52 Week Low
  • AUPH $5.20
  • SHCO $4.43
  • 52 Week High
  • AUPH $10.67
  • SHCO $8.47
  • Technical
  • Relative Strength Index (RSI)
  • AUPH 40.36
  • SHCO 72.94
  • Support Level
  • AUPH $7.29
  • SHCO $7.21
  • Resistance Level
  • AUPH $8.86
  • SHCO $7.46
  • Average True Range (ATR)
  • AUPH 0.34
  • SHCO 0.25
  • MACD
  • AUPH -0.06
  • SHCO 0.06
  • Stochastic Oscillator
  • AUPH 19.37
  • SHCO 87.30

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

About SHCO Soho House & Co Inc.

Soho House & Co Inc is a membership platform of physical and digital spaces that connects a vibrant, diverse group of members from across the world. The members use the platform to work, socialize, connect, create, and flourish all over the world. It offers lease agreements for Houses, hotels, restaurants, studios, spas, and other properties. The company's reportable segments are: United Kingdom; The Americas; and Europe and Rest of the world. The majority of its revenue is generated from the Americas segment, which encompasses its operating units in the Americas, including Soho Houses, stand-alone U.S. restaurants, Soho Friends, and the management fees under a hotel management contract for the operation of The Ned London.

Share on Social Networks: